A Real-world Study on the Prognosis of Patients with Pancreatic Cancer: A Prospective Stationary Survey from 2007-2020
Abstract
Objective Pancreatic cancer (PC) is one of the most refractory malignancies with a poor prognosis. However, improvements in the PC prognosis over time have not yet been thoroughly evaluated.We herein present a retrospective analysis of a prospectively maintained hospital-based cancer registry over 14 years. Methods The patients were prospectively enrolled in a Japanese government study. The period from 2007 to 2020 was divided into two seven-year periods to assess a prognostic improvement. The most recent censorship date is December 2024. Prognostic trends were compared across three treatment modalities: surgery, chemotherapy, and best supportive care (BSC). Results A total of 26,379 patients with all cancer types were prospectively enrolled over 14 years. Among these, 711 (2.7%) were enrolled for PC. Dichotomizing the period into the first and second halves, both the surgery group (18.7 months vs. 48.5 months, HR 0.45, P <0.001) and the chemotherapy group (9.1 months vs. 12.0 months, HR 0.58, P <0.001) had significantly better outcomes in the second half than in the first half. In the surgery group, the tumors were significantly smaller (P = 0.001) and detected earlier in the second half than in the first half (P = 0.007). In the chemotherapy group, the first-line treatment shifted from gemcitabine to gemcitabine plus nab-paclitaxel (GnP) in the second half (P <0.001). No significant improvement in the prognosis was observed in the BSC group (P = 0.597). Conclusions Prospective real-world data from 2007 to 2020 revealed that improvements in the early detection and adoption of GnP were temporally associated with an improved survival in patients with PC.
Related
- Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study
- PPARδ Expression and Prognosis in Resected Pancreatic Cancer: A Retrospective Single-Centre Study
- Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer.
- Autophagy and intratumoral bacteria abundance influence the prognosis of patients with pancreatic carcinoma.
- Implementation of risk prediction models using electronic health data for early detection of pancreatic cancer: a prospective pilot feasibility study
BibTeX
@article{abe2026realworld,
title = {{A Real-world Study on the Prognosis of Patients with Pancreatic Cancer: A Prospective Stationary Survey from 2007-2020}},
author = {Akinori Abe and Hiroshi Ohyama and Yoshiki Asahina and Kowa Nagasaka and Shodai Tohyama and Hiroyuki Amano and Shinya Takaoka and Yushi Imai and Sumio Hirose and Yukiko Asakawa and Ritsuko Yokouchi and Naho Sato and Yuko Hasegawa and Atsushi Takano and Yuji Iimuro and Yuichiro Kojima and Hitoshi Mochizuki and Jun Kato and Masao Omata},
journal = {Internal Medicine},
year = {2026},
month = nov,
doi = {10.2169/internalmedicine.6719-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/21/65_6719-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A Real-world Study on the Prognosis of Patients with Pancreatic Cancer: A Prospective Stationary Survey from 2007-2020
AU - Akinori Abe
AU - Hiroshi Ohyama
AU - Yoshiki Asahina
AU - Kowa Nagasaka
AU - Shodai Tohyama
AU - Hiroyuki Amano
AU - Shinya Takaoka
AU - Yushi Imai
AU - Sumio Hirose
AU - Yukiko Asakawa
AU - Ritsuko Yokouchi
AU - Naho Sato
AU - Yuko Hasegawa
AU - Atsushi Takano
AU - Yuji Iimuro
AU - Yuichiro Kojima
AU - Hitoshi Mochizuki
AU - Jun Kato
AU - Masao Omata
PY - 2026
DA - 2026/11/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6719-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/21/65_6719-25/_article
AB - Objective Pancreatic cancer (PC) is one of the most refractory malignancies with a poor prognosis. However, improvements in the PC prognosis over time have not yet been thoroughly evaluated.We herein present a retrospective analysis of a prospectively maintained hospital-based cancer registry over 14 years. Methods The patients were prospectively enrolled in a Japanese government study. The period from 2007 to 2020 was divided into two seven-year periods to assess a prognostic improvement. The most recent censorship date is December 2024. Prognostic trends were compared across three treatment modalities: surgery, chemotherapy, and best supportive care (BSC). Results A total of 26,379 patients with all cancer types were prospectively enrolled over 14 years. Among these, 711 (2.7%) were enrolled for PC. Dichotomizing the period into the first and second halves, both the surgery group (18.7 months vs. 48.5 months, HR 0.45, P <0.001) and the chemotherapy group (9.1 months vs. 12.0 months, HR 0.58, P <0.001) had significantly better outcomes in the second half than in the first half. In the surgery group, the tumors were significantly smaller (P = 0.001) and detected earlier in the second half than in the first half (P = 0.007). In the chemotherapy group, the first-line treatment shifted from gemcitabine to gemcitabine plus nab-paclitaxel (GnP) in the second half (P <0.001). No significant improvement in the prognosis was observed in the BSC group (P = 0.597). Conclusions Prospective real-world data from 2007 to 2020 revealed that improvements in the early detection and adoption of GnP were temporally associated with an improved survival in patients with PC.
SN - 1349-7235
SN - 0918-2918
ER -